Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $29.82 Analyst target: $41.58 Upside: 39.44%
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients and autoimmune diseases in the United States and internationally. The company is headquartered in Monrovia, California.
See the full interactive analysis & chart →Informational only — not investment advice.